AAON, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AAON, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $385.72M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $397.11M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $399.02M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $237.57M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $137.83M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $33.92M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $40.85M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $38.13M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $42.95M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $36.38M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $107.59M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $168.56M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $177.62M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $100.38M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $58.76M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $18.89M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $20.46M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $17.80M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $21.85M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $17.27M | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.25M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $209.12M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $227.49M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $126.76M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $69.25M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $101.84M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $67.01M | Feb 28, 2022 |
| FY2019 | Sep 30, 2019 | $15.03M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $17.29M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $11.47M | Feb 27, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.20M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $47.30M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $43.70M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $46.80M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $16.60M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $17.40M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $14.80M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $13.50M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $13.00M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $12.00M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $239.48M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $188.01M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $171.54M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $110.82M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $68.60M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $60.49M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $52.08M | Feb 28, 2022 |
| FY2019 | Sep 30, 2019 | $12.37M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $12.91M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $13.68M | Feb 27, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $534.0K | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $192.53M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $158.90M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $61.32M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $61.18M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $128.81M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $97.93M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $54.86M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $57.99M | Feb 27, 2020 |
| FY2012 | Dec 31, 2012 | $51.17M | Mar 14, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.69B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.18B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $941.44M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $813.90M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $650.18M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $449.01M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $371.42M | Feb 25, 2021 |
| FY2019 | Sep 30, 2019 | $351.90M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $341.98M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $319.24M | Feb 27, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $81.89M | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | $81.89M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $85.73M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $3.23M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $3.23M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $3.23M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $830.30M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $755.31M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $612.84M | Feb 27, 2025 |
| FY2023 | Aug 16, 2023 | $100.0K | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | $461.66M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $384.31M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $345.50M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $286.30M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $249.24M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $237.02M | Feb 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.0K | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $14.0K | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $287.0K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $5.45M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.86M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $79.03M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $26.80M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.99M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $21.46M | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $24.15M | Feb 28, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 81.69M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 81.44M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 81.51M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 80.14M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 52.53M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 52.22M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 52.08M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 51.99M | Feb 27, 2020 |
| FY2019 | Dec 31, 2017 | 52.42M | Feb 27, 2020 |
| FY2017 | Dec 31, 2016 | 52.65M | Feb 27, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.60M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $26.10M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $26.40M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $22.90M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $19.90M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $19.80M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $16.60M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $16.70M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $13.70M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $12.70M | Feb 28, 2019 |